But... perhaps try to focus on the positives of providing affordable MM to patients in need... maybe? Financially, in time I think the scale take up will compensate for the reduced revenue per unit. Also... Europe has a larger high net worth patient base than down here. It's hit easy to rake something from an idea to medicine in a patients hand. Amidst all the shadows, keen an eye on that also.
Ann: Launch of New Product Line in Aus & NZ - Mercury Pharma, page-34
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.79M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 71 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 07.03am 29/07/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable